Prologue Medicines
Angela Norton currently serves as the VP and Head of Platform at Prologue Medicines since April 2024. Previously, Angela held the position of VP of Discovery Research at Dianthus Therapeutics, Inc. from May 2023 to November 2023. Prior to that, Angela was the VP of Research and Development and Head of Research at Dynamicure Biotechnology, where significant achievements included the delivery of two accepted INDs and initiation of a clinical trial in immuno-oncology while fostering a comprehensive Research team. Angela's extensive background includes a long tenure at Shire Pharmaceuticals, where several roles from Sr. Director to Sr. Scientist involved building teams and successfully delivering multiple therapeutic candidates and INDs. Angela holds a Bachelor's degree in Chemistry and Biology from St. Olaf College and a PhD in Biochemistry and Molecular Biology from the University of New Hampshire.
This person is not in any teams
This person is not in any offices
Prologue Medicines
1 followers
Prologue is designing powerful new medicines by unlocking the viral proteome. The company’s state-of-the-art DELVE™ Platform systematically identifies and evaluates viral proteins and their unique features for their potential to precisely regulate human physiology. By co-opting viral evolution, Prologue is expanding the functional boundaries of proteins encoded by the human genome to create new programmable medicines. Prologue was founded by Flagship Pioneering in 2021.